Summary
37 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue fell by 4.1% a year over the last 3 years.
- Out of every 100 USD of revenue, only 0.8 USD is left as net profit.
- Operating profit covers the interest on its debt only 2.7 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 30.3 USD for 1 USD of yearly profit. Over the last five years it was 8.6 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
Revenue grew by 2.6% a year over 5 years. Over the last 3 years it fell by 4.1% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 84 USD
- Research and development 1.0 USD
- Sales and administration 13 USD
- Taxes and other 1.2 USD
- Net profit 0.8 USD
Net profit, industry median (Medical - Devices) 6.5 USD
Out of every 100 USD of revenue, 0.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 5.2 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2013By product
- Industrial 50%
- Medical 32%
- Aerospace and Defense 18%
By region
The company reports no revenue by region.
Industrial brings in 50% of revenue.
Segments in detail